Ergomed PLC
LSE:ERGO
Intrinsic Value
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval ph... [ Read More ]
The intrinsic value of one ERGO stock under the Base Case scenario is 1 116.84 GBX. Compared to the current market price of 1 346 GBX, Ergomed PLC is Overvalued by 17%.
Valuation Backtest
Ergomed PLC
Run backtest to discover the historical profit from buying and selling ERGO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ergomed PLC
Current Assets | 66.9m |
Cash & Short-Term Investments | 26m |
Receivables | 38.3m |
Other Current Assets | 2.6m |
Non-Current Assets | 66.5m |
PP&E | 5.2m |
Intangibles | 55.9m |
Other Non-Current Assets | 5.5m |
Current Liabilities | 37.3m |
Accounts Payable | 4.3m |
Accrued Liabilities | 9.5m |
Other Current Liabilities | 23.5m |
Non-Current Liabilities | 5.2m |
Long-Term Debt | 1.4m |
Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
Ergomed PLC
Revenue
|
152.1m
GBP
|
Cost of Revenue
|
-90.2m
GBP
|
Gross Profit
|
61.9m
GBP
|
Operating Expenses
|
-41.1m
GBP
|
Operating Income
|
20.7m
GBP
|
Other Expenses
|
-5.7m
GBP
|
Net Income
|
15m
GBP
|
Free Cash Flow Analysis
Ergomed PLC
ERGO Profitability Score
Profitability Due Diligence
Ergomed PLC's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Ergomed PLC's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
ERGO Solvency Score
Solvency Due Diligence
Ergomed PLC's solvency score is 92/100. The higher the solvency score, the more solvent the company is.
Score
Ergomed PLC's solvency score is 92/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERGO Price Targets Summary
Ergomed PLC
According to Wall Street analysts, the average 1-year price target for ERGO is 1 434.29 GBX .
Shareholder Return
ERGO Price
Ergomed PLC
Average Annual Return | 106.21% |
Standard Deviation of Annual Returns | 69.38% |
Max Drawdown | -41% |
Market Capitalization | 683.5m GBX |
Shares Outstanding | 52 084 300 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.
Contact
IPO
Employees
Officers
The intrinsic value of one ERGO stock under the Base Case scenario is 1 116.84 GBX.
Compared to the current market price of 1 346 GBX, Ergomed PLC is Overvalued by 17%.